# Singapore IP Company, UK-Resident Owner: The IDI Box Meets UK CFC Rules > Holding IP in a Singapore company under the IP Development Incentive (5%/10%, ITA s.43X, nexus approach) while the family lives in the UK: UK CFC rules (TIOPA 2010 Part 9A), central management and control, and the substance both sides read. Last modified: 2026-08-19T23:07:00.000Z Canonical: https://wiki.private.law/en/singapore-ip-uk-resident-owner Topics: structures, investments Jurisdictions: singapore, uk Semantic tags: substance, tax-regime --- ## Concept The idea is attractive: move the intellectual property into a Singapore company, apply for the IP incentive, pay 5โ€“10% instead of UK rates, while the family stays in the UK. Both halves of that sentence are regulated: Singapore's incentive is conditioned on real R&D nexus, and the UK reads a UK-managed foreign company โ€” or a UK-controlled one โ€” as its own tax base. The structure survives only when the Singapore side is genuinely Singaporean. > ๐Ÿ’ก **Short answer. **Yes, IP can sit in a Singapore IP company under the IP Development Incentive โ€” an approved company pays a concessionary 5% or 10% rate on a percentage of qualifying IP income, where the percentage follows the OECD modified nexus approach: the benefit tracks R&D expenditure actually performed \(EDB circular; ITA s.43X โ€” verified at edb.gov.sg\). The UK side is the constraint: a company managed and controlled from the UK can become UK tax-resident outright; and under TIOPA 2010 Part 9A the CFC charge can apportion a UK-controlled foreign company's chargeable profits to UK corporate controllers with a 25%+ relevant interest \(legislation.gov.uk โ€” verified 2026-08-19\). For a family in the UK, the honest version is: R&D functions and decisions in Singapore, UK shareholders passive, and UK advice taken on the CFC/ToAA position before the move โ€” not after. ## The Singapore Side: What the IDI Actually Is The IP Development Incentive is Singapore's patent-box regime, administered by the EDB under s.43X of the Income Tax Act 1947 \(introduced in Budget 2017, effective 1 July 2018; EDB circular verified 2026-08-19 at [edb.gov.sg](https://www.edb.gov.sg/)\). Core parameters: - **Rate: **5% or 10% on a percentage of qualifying IP income \(the percentage follows the modified nexus approach โ€” benefits track R&D expenditure contributing to the IP\); for companies approved on or after 17 February 2024 the base rate can also be 15%, with at least +0.5% step-ups in the later five-year periods \(ITA s.43X\(5\)-\(6\) โ€” verified 2026-08-19 at sso.agc.gov.sg\). No new IDI approvals after 31 December 2028 \(s.43X\(2\)\). - **Scope: **royalties and other income from elected qualifying IP rights โ€” patents and copyright in software; the election into the regime is irrevocable. - **Term: **an initial incentive period of up to ten years, extendable in periods of up to ten years each, with progress reporting to EDB and revocation for breach. - **Conditions: **expansionary projects and substantive economic activities in Singapore; arm's-length related-party dealing with contemporaneous transfer-pricing documentation submittable to IRAS. ## The UK Side: Two Ways the UK Reaches the Company Residence first: under UK case law a company is UK-resident if its central management and control is exercised in the UK โ€” board-level decisions by UK-resident family members can move the company's residence wholesale, before any CFC analysis begins \(verify current HMRC practice at [gov.uk](https://www.gov.uk/guidance/controlled-foreign-companies)\). CFC second: Part 9A of TIOPA 2010 charges UK corporate controllers holding a 25%+ relevant interest in a UK-controlled foreign company on an apportioned share of its chargeable profits at UK corporation tax rates, with credit for foreign tax โ€” IP-derived income is squarely within the gateway categories the regime targets \(legislation.gov.uk, TIOPA 2010 Part 9A โ€” verified 2026-08-19\). For individual family shareholders, the transfer-of-assets-abroad code \(ITA 2007, s.721 ff.\) is the parallel personal-level risk: income of the foreign company can be treated as the individual's where value was transferred abroad and the transferor can enjoy it. Both regimes have exemptions and motive defences โ€” but they are pleaded with evidence, not asserted. ## The Substance Question Both Sides Ask The IDI's nexus condition and the UK's management test point at the same facts: who does the R&D, where, and who decides. If the family's UK members perform the DEMPE functions โ€” development, enhancement, maintenance, protection, exploitation โ€” from the UK, the Singapore percentage shrinks toward zero on the nexus formula and the UK argument grows. The working version: R&D teams and IP decisions in Singapore, UK family members as passive shareholders with documented non-involvement in management, and a written motive narrative for why the IP sits in Asia \(market, team, history\) โ€” see [economic substance](https://wiki.private.law/en/economic-substance) and [Singapore holding ร— EU founders](https://wiki.private.law/en/singapore-holding-eu-founders) for the management-layer mechanics. ## Q/A ### How do UK CFC rules see the Singapore IP company? Two doors: if central management and control is exercised from the UK, the company risks becoming UK-resident outright; otherwise, TIOPA 2010 Part 9A can charge UK corporate controllers \(25%+ relevant interest\) on apportioned chargeable profits of the UK-controlled foreign company, and the transfer-of-assets-abroad rules can reach individual transferors. IP income is a classic target category. Exemptions exist but are evidenced, not assumed โ€” verify the current position with HMRC guidance and UK counsel. ### What substance does the Singapore IP box require? The IDI runs on the modified nexus approach: the concessionary 5%/10% rate applies to the proportion of qualifying IP income that tracks qualifying R&D expenditure, so the R&D must actually happen โ€” ideally in Singapore โ€” for the benefit to be material. Add EDB's award conditions: expansionary investment, substantive activities, progress reporting, and full transfer-pricing documentation for related-party flows \(EDB circular; ITA s.43X โ€” verified 2026-08-19\). ### Can the family stay in the UK and keep the benefit? Yes โ€” as passive shareholders, not as managers. The family can live in the UK while the Singapore company employs the R&D team, holds the board there and takes the IP decisions there. What the family cannot do is run the company from UK kitchens: that collapses both the nexus percentage and the UK residence/CFC position. UK personal reporting \(and any ToAA exposure\) is reviewed individually. *\*Reviewed: 2026-08-19 ยท Sources: *[*ITA s.43X \(sso.agc.gov.sg\) + EDB โ€” IP Development Incentive circular*](https://www.edb.gov.sg/)* \(verified 2026-08-19\); *[*legislation.gov.uk โ€” TIOPA 2010 Part 9A \(CFC\)*](https://www.legislation.gov.uk/ukpga/2010/4)* and ITA 2007 s.721 ff. \(verified 2026-08-19\); HMRC CFC guidance โ€” verify current practice at gov.uk.\** Cite as: wiki.private.law โ€” "Singapore IP Company, UK-Resident Owner: The IDI Box Meets UK CFC Rules", https://wiki.private.law/en/singapore-ip-uk-resident-owner \(reviewed 2026-08-19\). --- ## Sources - [Singapore EDB โ€” IP Development Incentive circular](https://www.edb.gov.sg/) \(verified 2026-08-19\) - [legislation.gov.uk โ€” Taxation \(International and Other Provisions\) Act 2010, Part 9A](https://www.legislation.gov.uk/ukpga/2010/4) \(verified 2026-08-19\) - [HMRC โ€” controlled foreign companies guidance](https://www.gov.uk/guidance/controlled-foreign-companies) \(verify current practice\) --- ## FAQ ### How do UK CFC rules see the Singapore IP company? Two doors: if central management and control is exercised from the UK, the company risks becoming UK-resident outright; otherwise, TIOPA 2010 Part 9A can charge UK corporate controllers (25%+ relevant interest) on apportioned chargeable profits of the UK-controlled foreign company, and the transfer-of-assets-abroad rules can reach individual transferors. IP income is a classic target category. Exemptions exist but are evidenced, not assumed โ€” verify the current position with HMRC guidance and UK counsel. ### What substance does the Singapore IP box require? The IDI runs on the modified nexus approach: the concessionary 5%/10% rate applies to the proportion of qualifying IP income that tracks qualifying R&D expenditure, so the R&D must actually happen โ€” ideally in Singapore โ€” for the benefit to be material. Add EDB's award conditions: expansionary investment, substantive activities, progress reporting, and full transfer-pricing documentation for related-party flows (EDB circular; ITA s.43X โ€” verified 2026-08-19). ### Can the family stay in the UK and keep the benefit? Yes โ€” as passive shareholders, not as managers. The family can live in the UK while the Singapore company employs the R&D team, holds the board there and takes the IP decisions there. What the family cannot do is run the company from UK kitchens: that collapses both the nexus percentage and the UK residence/CFC position. UK personal reporting (and any ToAA exposure) is reviewed individually. *Reviewed: 2026-08-19 ยท Sources: ITA s.43X (sso.agc.gov.sg) + EDB โ€” IP Development Incentive circular (verified 2026-08-19); legislation.gov.uk โ€” TIOPA 2010 Part 9A (CFC) and ITA 2007 s.721 ff. (verified 2026-08-19); HMRC CFC guidance โ€” verify current practice at gov.uk.* Cite as: wiki.private.law โ€” "Singapore IP Company, UK-Resident Owner: The IDI Box Meets UK CFC Rules", https://wiki.private.law/en/singapore-ip-uk-resident-owner (reviewed 2026-08-19). --- ## Factual claims - The idea is attractive: move the intellectual property into a Singapore company, apply for the IP incentive, pay 5โ€“10% instead of UK rates, while the family stays in the UK. - The IP Development Incentive is Singapore's patent-box regime, administered by the EDB under s.43X of the Income Tax Act 1947 (introduced in Budget 2017, effective 1 July 2018; EDB circular verified 2026-08-19 at edb.gov.sg).